Be the first to like this
Celgene Corp (NASDAQ: CELG) is one of biotechnology's brightest shining stars. The company markets a slate of therapies, including its mega blockbuster multiple myeloma drug Revlimid and its fast-growing cancer drug Abraxane.
Celgene also recently launched its first therapy for autoimmune disease, Otezla. Given all Celgene's activity, investors are right to wonder how sales stacked up in the second quarter. In the following slideshow, you'll learn which drugs grew fastest and why and gain insight into how the rest of the year is likely to shape up.
Clipping is a handy way to collect important slides you want to go back to later.